Exosome Research Market - Global Forecast to 2030
商品番号 : SMB-13952
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年6月 |
| ページ数 | 325 |
| 図表数 | 443 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本調査レポートでは、エクソソーム研究市場を、提供内容[キットおよび試薬（抗体、分離、精製、定量キット、試薬、およびその他のキットおよび試薬）、機器、サービス]、適応症[がん適応症（肺がん、乳がん、前立腺がん、大腸がん、その他のがん）、神経変性疾患、心血管疾患、感染症、およびその他の適応症]、用途[バイオマーカー、ワクチン開発、組織再生、およびその他の用途]、製造サービス[幹細胞由来エクソソーム製造サービス、樹状細胞由来エクソソーム製造サービス、およびその他の製造サービス]、エンドユーザー[学術機関および研究機関、製薬およびバイオテクノロジー企業、病院および臨床検査室]、および地域[北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ]別に分類しています。
本レポートは、エクソソーム研究市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。エクソソーム研究市場に関連する新たな承認／発売、提携、買収、および最近の動向についても解説しています。
The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities.
世界のエクソソーム研究市場は、2025年の2億1,440万米ドルから2030年には4億8,060万米ドルに達し、予測期間中に年平均成長率（CAGR）17.5%で成長すると予測されています。エクソソーム研究市場の拡大は、主にがん、神経変性疾患、心血管疾患（CVD）などの慢性疾患の発症率の上昇によって促進されており、この傾向は、新たな診断・治療戦略の緊急の必要性を浮き彫りにしています。エクソソームは、潜在的なバイオマーカーとしての特性と、標的を絞った治療薬の送達を促進する能力により、高度な疾患診断および治療法に対する高まる需要に応える上で独自の位置を占めています。
“The kits & reagents segment is expected to grow at the highest CAGR during the study period.”
As academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and analysis. The standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and monitoring. With the growing interest in exosome-based diagnostics—especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer’s and Parkinson’s—laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted therapies.
“North America is expected to grow at the highest CAGR in the global exosome research market from 2025 to 2030.”
North America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple University. Their investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America’s status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research sector.
In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side-70% and Demand Side-30%
- By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
- By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%
List of Key Companies Profiled in the Report:
Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), Danaher Corporation (US), Capricor Therapeutics(US), Lonza (Switzerland), QIAGEN (Germany), Creative Medical Technologies Holdings, Inc. (US), System Biosciences, LLC (US), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), Creative Biolabs (US), Nanofcm (UK), Izon Science (UK), and Malvern Panalytical (UK).
Research Coverage:
This research report categorizes the exosome research market by offering [kits & reagents (antibodies, isolation, purification, quantitation kits, reagents, and other kits & reagents), instruments, and services], indication [cancer indication (lung cancer, breast cancer, prostate cancer, colorectal cancer, other cancers), neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications], by application [biomarkers, vaccine development, tissue regeneration, and other applications], by manufacturing services [stem cell-derived exosome manufacturing services, dendritic cell-derived exosome manufacturing services, and other manufacturing services] by end user [academic & research institutes, pharmaceutical & biotechnological companies, and hospitals & clinical laboratories] and by region [North America, Europe, Asia Pacific, Latin America, Middle East & Africa].
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the exosome research market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the Exosome Research market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market.
- Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 32
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32
1.3.2 INCLUSIONS & EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 33
1.3.4 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 34
1.5 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Objectives of secondary research 37
2.1.1.2 Key data from secondary sources 38
2.1.2 PRIMARY DATA 38
2.1.2.1 Breakdown of primaries 39
2.1.2.2 Key objective of primary research 39
2.2 MARKET ESTIMATION 40
2.2.1 GLOBAL MARKET ESTIMATION 41
2.2.1.1 Company revenue analysis (bottom-up approach) 41
2.2.1.2 Revenue share analysis of Thermo Fisher Scientific Inc. 42
2.2.1.3 MnM repository analysis 42
2.2.1.4 Primary interviews 43
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 43
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 44
2.3 MARKET GROWTH RATE PROJECTIONS 45
2.4 DATA TRIANGULATION 47
2.5 STUDY ASSUMPTIONS 47
2.6 RESEARCH LIMITATIONS 48
2.7 RISK ANALYSIS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 53
4.1 EXOSOME RESEARCH MARKET OVERVIEW 53
4.2 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION AND COUNTRY 54
4.3 EXOSOME RESEARCH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing investment in pharmaceutical and life sciences R&D 57
5.2.1.2 Rising focus on development of cancer therapeutics and diagnostics 58
5.2.1.3 Growing interest in exosome-based procedures 59
5.2.2 RESTRAINTS 60
5.2.2.1 Technical complexity of exosome isolation and characterization 60
5.2.2.2 Regulatory complications and uncertainty in exosome research 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 High investments in emerging economies 61
5.2.3.2 Growing interest in exosome-based therapeutics 61
5.2.3.3 Rising demand for personalized medicines 62
5.2.4 CHALLENGES 63
5.2.4.1 Lack of standard protocols for exosome manufacturing and development 63
5.2.4.2 Limited understanding of cargo loading capacity 63
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 64
5.4 PRICING ANALYSIS 64
5.4.1 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS,
BY KEY PLAYER, 2024 65
5.4.2 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024 66
5.5 VALUE CHAIN ANALYSIS 68
5.6 SUPPLY CHAIN ANALYSIS 69
5.7 ECOSYSTEM ANALYSIS 70
5.7.1 ROLE IN ECOSYSTEM 71
5.8 TECHNOLOGY ANALYSIS 72
5.8.1 KEY TECHNOLOGIES 72
5.8.1.1 Ultracentrifugation 72
5.8.1.2 Nanoparticle tracking analysis (NTA) 72
5.8.2 COMPLIMENTARY TECHNOLOGIES 72
5.8.2.1 Microfluidics 72
5.8.2.2 Western blotting/ELISA 72
5.8.3 ADJACENT TECHNOLOGIES 73
5.8.3.1 Next-generation sequencing 73
5.8.3.2 Mass spectrometry 73
5.9 PATENT ANALYSIS 73
5.9.1 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 73
5.9.2 LIST OF KEY PATENTS, 2023–2024 75
5.10 KEY CONFERENCES & EVENTS, 2025–2026 76
5.11 REGULATORY ANALYSIS 77
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
5.11.2 REGULATORY FRAMEWORK 80
5.11.2.1 North America 80
5.11.2.1.1 US 80
5.11.2.1.2 Canada 81
5.11.2.2 Europe 81
5.11.2.2.1 Germany 81
5.11.2.2.2 France 82
5.11.2.2.3 UK 82
5.11.2.3 Asia Pacific 82
5.11.2.3.1 China 82
5.11.2.3.2 Japan 83
5.11.2.3.3 India 83
5.11.2.4 Rest of the World 83
5.11.2.4.1 Brazil 83
5.11.2.4.2 Argentina 84
5.11.2.4.3 Saudi Arabia 84
5.12 PORTER’S FIVE FORCES ANALYSIS 84
5.12.1 THREAT OF NEW ENTRANTS 85
5.12.2 THREAT OF SUBSTITUTES 86
5.12.3 BARGAINING POWER OF SUPPLIERS 86
5.12.4 BARGAINING POWER OF BUYERS 86
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 87
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.13.2 KEY BUYING CRITERIA 88
5.14 INVESTMENT & FUNDING SCENARIO 90
5.15 TRADE DATA ANALYSIS 91
5.15.1 IMPORT DATA FOR HS CODE 3822, 2020–2024 91
5.15.2 EXPORT DATA FOR HS CODE 3822, 2020–2024 93
5.16 IMPACT OF AI/GEN AI ON EXOSOME RESEARCH MARKET 94
5.17 IMPACT OF 2025 US TARIFF ON EXOSOME RESEARCH MARKET 95
5.17.1 INTRODUCTION 95
5.17.2 KEY TARIFF RATES 96
5.17.3 PRICE IMPACT ANALYSIS 97
5.17.4 IMPACTS ON COUNTRY/REGION 98
5.17.4.1 North America 98
5.17.4.1.1 US 98
5.17.4.2 Europe 99
5.17.4.3 Asia Pacific 99
5.17.5 IMPACT ON END-USE INDUSTRIES 99
5.17.5.1 Academic & research institutes 99
5.17.5.2 Pharmaceutical & biotechnology companies 100
5.17.5.3 Hospitals & clinical laboratories 100
6 EXOSOME RESEARCH MARKET, BY OFFERING 101
6.1 INTRODUCTION 102
6.2 KITS & REAGENTS 102
6.2.1 ANTIBODIES 105
6.2.1.1 High demand for exosome-based markers for disease detection to propel market growth 105
6.2.2 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS 108
6.2.2.1 Availability of rapid and easy-to-use kits & reagents to ensure sustained demand 108
6.2.3 OTHER KITS & REAGENTS 110
6.3 INSTRUMENTS 113
6.3.1 DEMAND FOR SCALABLE EXOSOME DEVELOPMENT THROUGH HIGH-THROUGHPUT SYSTEMS TO DRIVE GROWTH 113
6.4 SERVICES 116
6.4.1 LACK OF IN-HOUSE RESOURCES TO SUPPORT MARKET GROWTH 116
7 EXOSOME RESEARCH MARKET, BY INDICATION 119
7.1 INTRODUCTION 120
7.2 CANCER 120
7.2.1 LUNG CANCER 123
7.2.1.1 Increasing demand for advanced diagnostics for lung cancer to propel market growth 123
7.2.2 BREAST CANCER 126
7.2.2.1 Increased awareness and focus on better non-invasive diagnosis to aid market growth 126
7.2.3 PROSTATE CANCER 128
7.2.3.1 Effectiveness of liquid biopsy in detecting prostate cancer before surgery to support market growth 128
7.2.4 COLORECTAL CANCER 131
7.2.4.1 Rising focus on exosome-based research on tumor initiation, progression, chemoresistance, and metastasis to drive market 131
7.2.5 OTHER CANCERS 133
7.3 NEURODEGENERATIVE DISEASES 136
7.3.1 INCREASED APPLICATION OF SALIVARY EXOSOMAL CARGO CONTENT IN DISEASE TREATMENT TO PROPEL MARKET GROWTH 136
7.4 CARDIOVASCULAR DISEASES 139
7.4.1 GREATER RESEARCH FOCUS ON EXTRACELLULAR VESICLES TO AUGMENT MARKET GROWTH 139
7.5 INFECTIOUS DISEASES 141
7.5.1 POTENTIAL FOR EXOSOMES IN DEVELOPING NOVEL INFECTIOUS DISEASE TREATMENTS TO AID ADOPTION 141
7.6 OTHER INDICATIONS 144
8 EXOSOME RESEARCH MARKET, BY APPLICATION 147
8.1 INTRODUCTION 148
8.2 BIOMARKERS 148
8.2.1 ABILITY TO MODULATE CELL SIGNALING AND REDUCE NEUROINFLAMMATION TO DRIVE ADOPTION 148
8.3 VACCINE DEVELOPMENT 151
8.3.1 NEED FOR COMBATING INFECTIOUS DISEASES TO SPUR ADOPTION OF EXOSOME-BASED VACCINES 151
8.4 TISSUE REGENERATION 154
8.4.1 MINIMAL SIDE EFFECTS AND HIGH EFFICACY OF EXOSOMES IN TISSUE REGENERATION TO SUPPORT ADOPTION 154
8.5 OTHER APPLICATIONS 157
9 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE 160
9.1 INTRODUCTION 161
9.2 STEM CELL-DERIVED EXOSOME MANUFACTURING 161
9.2.1 INCREASE IN DEMAND FOR MESENCHYMAL STEM CELLS-BASED EXOSOMES IN THERAPEUTICS TO AUGMENT MARKET GROWTH 161
9.3 DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING 162
9.3.1 SIGNIFICANT DEVELOPMENTS IN DENDRITIC CELL-BASED EXOSOME IMMUNOTHERAPY TO DRIVE MARKET 162
9.4 OTHER MANUFACTURING SERVICES 162
10 EXOSOME RESEARCH MARKET, BY END USER 163
10.1 INTRODUCTION 164
10.2 ACADEMIC & RESEARCH INSTITUTES 164
10.2.1 INCREASING NUMBER OF CANCER AND STEM CELL RESEARCH PROJECTS GLOBALLY TO AUGMENT MARKET GROWTH 164
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 167
10.3.1 HIGH INVESTMENTS AND RAPID INNOVATIONS IN EXOSOME-BASED DIAGNOSTICS TO AID MARKET GROWTH 167
10.4 HOSPITALS & CLINICAL TESTING LABORATORIES 170
10.4.1 RISING ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO PROPEL MARKET GROWTH 170
11 EXOSOME RESEARCH MARKET, BY REGION 173
11.1 INTRODUCTION 174
11.2 NORTH AMERICA 175
11.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA 176
11.2.2 US 180
11.2.2.1 US to dominate North American exosome research market during study period 180
11.2.3 CANADA 183
11.2.3.1 Increasing funding for genome-based medical treatments to support market growth 183
11.3 EUROPE 186
11.3.1 MACROECONOMIC ANALYSIS FOR EUROPE 186
11.3.2 GERMANY 190
11.3.2.1 Advanced biotechnology sector and developed research facilities to favor market growth 190
11.3.3 UK 193
11.3.3.1 Favorable R&D initiatives and advanced life science industry to drive market 193
11.3.4 FRANCE 196
11.3.4.1 Increasing collaborations between biotechnology firms and research institutes to propel market growth 196
11.3.5 ITALY 199
11.3.5.1 Favorable government policies to propel growth of exosome research 199
11.3.6 SPAIN 201
11.3.6.1 Increased focus on pharmaceutical R&D to aid market growth 201
11.3.7 REST OF EUROPE 204
11.4 ASIA PACIFIC 206
11.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC 207
11.4.2 CHINA 210
11.4.2.1 Favorable government initiatives for development of biotechnology industry to drive market 210
11.4.3 JAPAN 213
11.4.3.1 High prevalence of cancer and increased healthcare expenditure to aid market growth 213
11.4.4 INDIA 216
11.4.4.1 Increasing number of institutional alliances and growing focus on clinical innovation to support market growth 216
11.4.5 AUSTRALIA 218
11.4.5.1 Substantial government funding and innovative applications in regenerative medicines to augment market growth 218
11.4.6 SOUTH KOREA 221
11.4.6.1 Favorable government initiatives and routine clinical trials to support market growth 221
11.4.7 REST OF ASIA PACIFIC 224
11.5 LATIN AMERICA 227
11.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA 227
11.5.2 BRAZIL 231
11.5.2.1 Increased government investments in pharmaceutical R&D to drive market 231
11.5.3 MEXICO 234
11.5.3.1 Advancements in regenerative medicines and exosome-based therapies to support market growth 234
11.5.4 REST OF LATIN AMERICA 236
11.6 MIDDLE EAST & AFRICA 239
11.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA 239
11.6.2 GCC COUNTRIES 243
11.6.2.1 Strong focus on local pharmaceutical R&D to fuel market growth 243
11.6.3 REST OF MIDDLE EAST & AFRICA 246
12 COMPETITIVE LANDSCAPE 250
12.1 INTRODUCTION 250
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 250
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET 250
12.3 REVENUE ANALYSIS, 2020–2024 252
12.4 MARKET SHARE ANALYSIS, 2024 253
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 255
12.5.1 STARS 255
12.5.2 EMERGING LEADERS 255
12.5.3 PERVASIVE PLAYERS 256
12.5.4 PARTICIPANTS 256
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 257
12.5.5.1 Company footprint 257
12.5.5.2 Region footprint 258
12.5.5.3 Offering footprint 259
12.5.5.4 Indication footprint 260
12.5.5.5 Application footprint 261
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 261
12.6.1 PROGRESSIVE COMPANIES 261
12.6.2 RESPONSIVE COMPANIES 262
12.6.3 DYNAMIC COMPANIES 262
12.6.4 STARTING BLOCKS 262
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 263
12.6.5.1 Detailed list of key startups/SMEs 263
12.6.5.2 Competitive benchmarking of key startups/SME players, by offering and region 264
12.7 COMPANY VALUATION & FINANCIAL METRICS 265
12.7.1 FINANCIAL METRICS 265
12.7.2 COMPANY VALUATION 265
12.8 BRAND/PRODUCT COMPARISON 266
12.9 COMPETITIVE SCENARIO 267
12.9.1 PRODUCT LAUNCHES & APPROVALS 267
12.9.2 DEALS 268
12.9.3 EXPANSIONS 269
13 COMPANY PROFILES 270
13.1 KEY PLAYERS 270
13.1.1 THERMO FISHER SCIENTIFIC INC. 270
13.1.1.1 Business overview 270
13.1.1.2 Products/Services/Solutions offered 271
13.1.1.3 Recent developments 273
13.1.1.3.1 Deals 273
13.1.1.4 MnM view 273
13.1.1.4.1 Key strengths 273
13.1.1.4.2 Strategic choices 273
13.1.1.4.3 Weaknesses & competitive threats 273
13.1.2 QIAGEN 274
13.1.2.1 Business overview 274
13.1.2.2 Products/Services/Solutions offered 275
13.1.2.3 Recent developments 276
13.1.2.3.1 Product launches 276
13.1.2.4 MnM view 276
13.1.2.4.1 Key strengths 276
13.1.2.4.2 Strategic choices 276
13.1.2.4.3 Weaknesses & competitive threats 276
13.1.3 LONZA 277
13.1.3.1 Business overview 277
13.1.3.2 Products/Services/Solutions offered 278
13.1.3.3 Recent developments 279
13.1.3.3.1 Deals 279
13.1.3.3.2 Expansions 279
13.1.3.4 MnM view 279
13.1.3.4.1 Key strengths 279
13.1.3.4.2 Strategic choices 280
13.1.3.4.3 Weaknesses & competitive threats 280
13.1.4 DANAHER 281
13.1.4.1 Business overview 281
13.1.4.2 Products/Services/Solutions offered 283
13.1.4.3 Recent developments 283
13.1.4.3.1 Product launches 283
13.1.4.3.2 Deals 284
13.1.4.4 MnM view 284
13.1.4.4.1 Key strengths 284
13.1.4.4.2 Strategic choices 284
13.1.4.4.3 Weaknesses & competitive threats 284
13.1.5 BIO-TECHNE 285
13.1.5.1 Business overview 285
13.1.5.2 Products/Services/Solutions offered 286
13.1.5.3 Recent developments 287
13.1.5.3.1 Product launches 287
13.1.5.4 MnM view 287
13.1.5.4.1 Key strengths 287
13.1.5.4.2 Strategic choices 287
13.1.5.4.3 Weaknesses & competitive threats 287
13.1.6 SYSTEM BIOSCIENCES, LLC 288
13.1.6.1 Business overview 288
13.1.6.2 Products/Services/Solutions offered 288
13.1.7 AMSBIO 290
13.1.7.1 Business overview 290
13.1.7.2 Products/Services/Solutions offered 291
13.1.8 ROOSTERBIO, INC. 292
13.1.8.1 Business overview 292
13.1.8.2 Products/Services/Solutions offered 292
13.1.8.3 Recent developments 293
13.1.8.3.1 Deals 293
13.1.9 MILTENYI BIOTEC 294
13.1.9.1 Business overview 294
13.1.9.2 Products/Services/Solutions offered 294
13.1.9.3 Recent developments 295
13.1.9.3.1 Product launches 295
13.1.10 NORGEN BIOTEK CORP. 296
13.1.10.1 Business overview 296
13.1.10.2 Products/Services/Solutions offered 296
13.1.11 AETHLON MEDICAL, INC. 298
13.1.11.1 Business overview 298
13.1.11.2 Products/Services/Solutions offered 299
13.1.11.3 Recent developments 299
13.1.11.3.1 Product approvals 299
13.1.12 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC. 300
13.1.12.1 Business overview 300
13.1.12.2 Products/Services/Solutions offered 300
13.1.13 SPECTRIS 301
13.1.13.1 Business overview 301
13.1.13.2 Products/Services/Solutions offered 302
13.1.13.3 Recent developments 303
13.1.13.3.1 Product launches 303
13.1.13.3.2 Deals 303
13.1.14 NANOFCM, INC. 304
13.1.14.1 Business overview 304
13.1.14.2 Products/Services/Solutions offered 304
13.1.15 IZON SCIENCE LIMITED 305
13.1.15.1 Business overview 305
13.1.15.2 Products/Services/Solutions offered 305
13.1.16 CAPRICOR THERAPEUTICS, INC. 306
13.1.16.1 Business overview 306
13.1.16.2 Products/Services/Solutions offered 307
13.2 OTHER PLAYERS 308
13.2.1 ANJARIUM BIOSCIENCES AG 308
13.2.2 CILOA 308
13.2.3 INNOVAPREP 309
13.2.4 ILIAS BIOLOGICS INC. 309
13.2.5 UNCHAINED LABS 310
13.2.6 RION INC. 310
13.2.7 CELL GUIDANCE SYSTEM LLC 311
13.2.8 INOVIQ 312
13.2.9 NX PHARMAGEN 312
13.2.10 EXOPHARM 313
13.2.11 EVERZOM 314
13.2.12 NANOSOMIX 314
13.2.13 CREATIVE BIOLABS 315
14 APPENDIX 317
14.1 DISCUSSION GUIDE 317
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 321
14.3 CUSTOMIZATION OPTIONS 323
14.4 RELATED REPORTS 323
14.5 AUTHOR DETAILS 324
LIST OF TABLES
TABLE 1 EXOSOME RESEARCH MARKET: INCLUSIONS & EXCLUSIONS 33
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 46
TABLE 3 EXOSOME RESEARCH MARKET: RISK ANALYSIS 48
TABLE 4 EXOSOME RESEARCH MARKET: IMPACT ANALYSIS 57
TABLE 5 GLOBAL CANCER INCIDENCE, BY REGION, 2022 VS. 2025 58
TABLE 6 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY KEY PLAYER, 2024 65
TABLE 7 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION, 2024 (USD) 67
TABLE 8 EXOSOME RESEARCH MARKET: ROLE IN ECOSYSTEM 71
TABLE 9 EXOSOME RESEARCH MARKET: NUMBER OF PATENTS FILED, 2014–2024 73
TABLE 10 EXOSOME RESEARCH MARKET: DETAILED ANALYSIS OF
KEY PATENTS, 2023–2024 75
TABLE 11 EXOSOME RESEARCH MARKET: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025–DECEMBER 2026 76
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 16 EXOSOME RESEARCH MARKET: PORTER’S FIVE FORCES 84
TABLE 17 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 87
TABLE 18 KEY BUYING CRITERIA FOR TOP THREE END USERS 89
TABLE 19 IMPORT DATA FOR HS CODE 3822, 2020–2024 (USD THOUSAND) 92
TABLE 20 EXPORT DATA FOR HS CODE 3822, 2020–2024 (USD THOUSAND) 93
TABLE 21 US ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 22 EXOSOME RESEARCH PRODUCTS-RELATED TARIFF REVISION 96
TABLE 23 EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 102
TABLE 24 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 25 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 26 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 27 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 28 LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 29 MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 104
TABLE 30 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 105
TABLE 31 ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 32 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 33 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 34 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 35 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 36 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY REGION,
2023–2030 (USD MILLION) 107
TABLE 37 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 108
TABLE 38 NORTH AMERICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 39 EUROPE: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 40 ASIA PACIFIC: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 41 LATIN AMERICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 42 MIDDLE EAST & AFRICA: ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 43 OTHER KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 44 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 45 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 46 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 47 LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 48 MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 112
TABLE 49 EXOSOME RESEARCH INSTRUMENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 113
TABLE 50 NORTH AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 51 EUROPE: EXOSOME RESEARCH INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: EXOSOME RESEARCH INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 53 LATIN AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 54 MIDDLE EAST & AFRICA: EXOSOME RESEARCH INSTRUMENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 115
TABLE 55 EXOSOME RESEARCH SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 56 NORTH AMERICA: EXOSOME RESEARCH SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 57 EUROPE: EXOSOME RESEARCH SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 58 ASIA PACIFIC: EXOSOME RESEARCH SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 59 LATIN AMERICA: EXOSOME RESEARCH SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 60 MIDDLE EAST & AFRICA: EXOSOME RESEARCH SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 118
TABLE 61 EXOSOME RESEARCH MARKET, BY INDICATION, 2023–2030 (USD MILLION) 120
TABLE 62 EXOSOME RESEARCH MARKET FOR CANCER, BY REGION,
2023–2030 (USD MILLION) 121
TABLE 63 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 64 EUROPE: EXOSOME RESEARCH MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 66 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 67 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY REGION, 2023–2030 (USD MILLION) 122
TABLE 68 EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE, 2023–2030 (USD MILLION) 123
TABLE 69 LUNG CANCER MARKET, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 70 NORTH AMERICA: LUNG CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 71 EUROPE: LUNG CANCER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 72 ASIA PACIFIC: LUNG CANCER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 73 LATIN AMERICA: LUNG CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 74 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY REGION,
2023–2030 (USD MILLION) 125
TABLE 75 BREAST CANCER MARKET, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 76 NORTH AMERICA: BREAST CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 77 EUROPE: BREAST CANCER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 78 ASIA PACIFIC: BREAST CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 79 LATIN AMERICA: BREAST CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 80 MIDDLE EAST & AFRICA: BREAST CANCER MARKET,
BY REGION, 2023–2030 (USD MILLION) 128
TABLE 81 PROSTATE CANCER MARKET, BY REGION, 2023–2030 (USD MILLION) 129
TABLE 82 NORTH AMERICA: PROSTATE CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 129
TABLE 83 EUROPE: PROSTATE CANCER MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 84 ASIA PACIFIC: PROSTATE CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 85 LATIN AMERICA: PROSTATE CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 86 MIDDLE EAST & AFRICA: PROSTATE CANCER MARKET,
BY REGION, 2023–2030 (USD MILLION) 131
TABLE 87 COLORECTAL CANCER MARKET, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 88 NORTH AMERICA: COLORECTAL CANCER MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 89 EUROPE: COLORECTAL CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 132
TABLE 90 ASIA PACIFIC: COLORECTAL CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 132
TABLE 91 LATIN AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 92 MIDDLE EAST & AFRICA: COLORECTAL CANCER MARKET,
BY REGION, 2023–2030 (USD MILLION) 133
TABLE 93 OTHER CANCERS MARKET, BY REGION, 2023–2030 (USD MILLION) 134
TABLE 94 NORTH AMERICA: OTHER CANCERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 95 EUROPE: OTHER CANCERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 96 ASIA PACIFIC: OTHER CANCERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 135
TABLE 97 LATIN AMERICA: OTHER CANCERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 135
TABLE 98 MIDDLE EAST & AFRICA: OTHER CANCERS MARKET,
BY REGION, 2023–2030 (USD MILLION) 135
TABLE 99 EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES,
BY REGION, 2023–2030 (USD MILLION) 136
TABLE 100 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 101 EUROPE: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 102 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 103 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 104 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 105 EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023–2030 (USD MILLION) 139
TABLE 106 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030(USD MILLION) 139
TABLE 107 EUROPE: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2023–2030(USD MILLION) 140
TABLE 108 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2023–2030(USD MILLION) 140
TABLE 109 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030(USD MILLION)) 141
TABLE 110 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030(USD MILLION) 141
TABLE 111 EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2023–2030 (USD MILLION) 142
TABLE 112 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 113 EUROPE: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 114 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 115 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 116 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 144
TABLE 117 EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS,
BY REGION, 2023–2030 (USD MILLION) 145
TABLE 118 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 119 EUROPE: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 120 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 121 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 122 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 123 EXOSOME RESEARCH MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148
TABLE 124 EXOSOME RESEARCH MARKET FOR BIOMARKERS,
BY REGION, 2023–2030 (USD MILLION) 149
TABLE 125 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 126 EUROPE: EXOSOME RESEARCH MARKET FOR BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 127 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 128 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR BIOMARKERS,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 129 MIDDLE EAST & AFRICA & AFRICA: EXOSOME RESEARCH MARKET
FOR BIOMARKERS, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 130 EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT,
BY REGION, 2023–2030 (USD MILLION) 152
TABLE 131 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 132 EUROPE: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 133 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 134 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 135 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 153
TABLE 136 EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION,
BY REGION, 2023–2030 (USD MILLION) 154
TABLE 137 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 138 EUROPE: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 139 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 140 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 141 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR TISSUE REGENERATION, BY REGION, 2023–2030 (USD MILLION) 156
TABLE 142 EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 157
TABLE 143 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 144 EUROPE: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 145 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 146 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 147 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 148 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE,
2023–2030 (USD MILLION) 161
TABLE 149 EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 164
TABLE 150 EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2023–2030 (USD MILLION) 165
TABLE 151 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR ACADEMIC &
RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 152 EUROPE: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 153 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 154 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 155 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 167
TABLE 156 EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 157 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 158 EUROPE: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 159 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 160 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 161 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 162 EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 163 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 164 EUROPE: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 165 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 166 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 167 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 168 EXOSOME RESEARCH MARKET: KEYWORD RELEVANCE, TREND,
AND PRIMARY FOCUS, 2015–2024 174
TABLE 169 EXOSOME RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 170 NORTH AMERICA: KEY MACROINDICATORS 177
TABLE 171 NORTH AMERICA: EXOSOME RESEARCH MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 172 NORTH AMERICA: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 178
TABLE 173 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 174 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 178
TABLE 175 NORTH AMERICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 176 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 179
TABLE 177 NORTH AMERICA: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 180
TABLE 178 US: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 181
TABLE 179 US: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 181
TABLE 180 US: EXOSOME RESEARCH MARKET, BY INDICATION, 2023–2030 (USD MILLION) 181
TABLE 181 US: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE,
2023–2030 (USD MILLION) 182
TABLE 182 US: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182
TABLE 183 US: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 182
TABLE 184 CANADA: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 183
TABLE 185 CANADA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 186 CANADA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 184
TABLE 187 CANADA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 188 CANADA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 185
TABLE 189 CANADA: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 185
TABLE 190 EUROPE: KEY MACROINDICATORS 186
TABLE 191 EUROPE: EXOSOME RESEARCH MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 192 EUROPE: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 188
TABLE 193 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 194 EUROPE: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 189
TABLE 195 EUROPE: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 196 EUROPE: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 190
TABLE 197 EUROPE: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 198 GERMANY: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 191
TABLE 199 GERMANY: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 200 GERMANY: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 192
TABLE 201 GERMANY: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 202 GERMANY: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 203 GERMANY: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 193
TABLE 204 UK: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 194
TABLE 205 UK: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 206 UK: EXOSOME RESEARCH MARKET, BY INDICATION, 2023–2030 (USD MILLION) 194
TABLE 207 UK: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 195
TABLE 208 UK: EXOSOME RESEARCH MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195
TABLE 209 UK: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 210 FRANCE: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 196
TABLE 211 FRANCE: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 212 FRANCE: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 197
TABLE 213 FRANCE: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 214 FRANCE: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 215 FRANCE: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 216 ITALY: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 199
TABLE 217 ITALY: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 218 ITALY: EXOSOME RESEARCH MARKET, BY INDICATION, 2023–2030 (USD MILLION) 200
TABLE 219 ITALY: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 220 ITALY: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 221 ITALY: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 201
TABLE 222 SPAIN: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 201
TABLE 223 SPAIN: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 224 SPAIN: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 202
TABLE 225 SPAIN: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 226 SPAIN: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 203
TABLE 227 SPAIN: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 203
TABLE 228 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 204
TABLE 229 REST OF EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 230 REST OF EUROPE: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 205
TABLE 231 REST OF EUROPE: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 232 REST OF EUROPE: EXOSOME RESEARCH MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 206
TABLE 233 REST OF EUROPE: EXOSOME RESEARCH MARKET,
BY END USER, 2023–2030 (USD MILLION) 206
TABLE 234 ASIA PACIFIC: KEY MACROINDICATORS 207
TABLE 235 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 208
TABLE 236 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 208
TABLE 237 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 238 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 209
TABLE 239 ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 240 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 241 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 242 CHINA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 211
TABLE 243 CHINA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 244 CHINA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 212
TABLE 245 CHINA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 212
TABLE 246 CHINA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 213
TABLE 247 CHINA: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 248 JAPAN: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 214
TABLE 249 JAPAN: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 250 JAPAN: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 214
TABLE 251 JAPAN: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 252 JAPAN: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 215
TABLE 253 JAPAN: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 215
TABLE 254 INDIA: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 216
TABLE 255 INDIA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 217
TABLE 256 INDIA: EXOSOME RESEARCH MARKET, BY INDICATION, 2023–2030 (USD MILLION) 217
TABLE 257 INDIA: EXOSOME RESEARCH MARKET FOR CANCER, BY TYPE,
2023–2030 (USD MILLION) 217
TABLE 258 INDIA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 218
TABLE 259 INDIA: EXOSOME RESEARCH MARKET, BY END USER, 2023–2030 (USD MILLION) 218
TABLE 260 AUSTRALIA: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 219
TABLE 261 AUSTRALIA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 262 AUSTRALIA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 219
TABLE 263 AUSTRALIA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 264 AUSTRALIA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 265 AUSTRALIA: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 221
TABLE 266 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 222
TABLE 267 SOUTH KOREA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 268 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 223
TABLE 269 SOUTH KOREA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 270 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 224
TABLE 271 SOUTH KOREA: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 224
TABLE 272 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 225
TABLE 273 REST OF ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 274 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET,
BY INDICATION, 2023–2030 (USD MILLION) 225
TABLE 275 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 226
TABLE 276 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 226
TABLE 277 REST OF ASIA PACIFIC: EXOSOME RESEARCH MARKET,
BY END USER, 2023–2030 (USD MILLION) 227
TABLE 278 LATIN AMERICA: KEY MACROINDICATORS 228
TABLE 279 LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 228
TABLE 280 LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 229
TABLE 281 LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 282 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 229
TABLE 283 LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 284 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 230
TABLE 285 LATIN AMERICA: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 231
TABLE 286 BRAZIL: EXOSOME RESEARCH MARKET, BY OFFERING, 2023–2030 (USD MILLION) 232
TABLE 287 BRAZIL: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 288 BRAZIL: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 232
TABLE 289 BRAZIL: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 290 BRAZIL: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 233
TABLE 291 BRAZIL: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 233
TABLE 292 MEXICO: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 234
TABLE 293 MEXICO: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 294 MEXICO: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 235
TABLE 295 MEXICO: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 296 MEXICO: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 236
TABLE 297 MEXICO: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 236
TABLE 298 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 237
TABLE 299 REST OF LATIN AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 300 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY INDICATION, 2023–2030 (USD MILLION) 237
TABLE 301 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 302 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 238
TABLE 303 REST OF LATIN AMERICA: EXOSOME RESEARCH MARKET,
BY END USER, 2023–2030 (USD MILLION) 239
TABLE 304 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 240
TABLE 305 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY REGION, 2023–2030 (USD MILLION) 240
TABLE 306 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 240
TABLE 307 MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 308 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY INDICATION, 2023–2030 (USD MILLION) 241
TABLE 309 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 310 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 242
TABLE 311 MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY END USER, 2023–2030 (USD MILLION) 243
TABLE 312 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY OFFERING,
2023–2030 (USD MILLION) 243
TABLE 313 GCC COUNTRIES: EXOSOME RESEARCH KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 314 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY INDICATION,
2023–2030 (USD MILLION) 244
TABLE 315 GCC COUNTRIES: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 316 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 245
TABLE 317 GCC COUNTRIES: EXOSOME RESEARCH MARKET, BY END USER,
2023–2030 (USD MILLION) 246
TABLE 318 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 246
TABLE 319 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 320 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY INDICATION, 2023–2030 (USD MILLION) 247
TABLE 321 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET FOR CANCER,
BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 322 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 248
TABLE 323 REST OF MIDDLE EAST & AFRICA: EXOSOME RESEARCH MARKET,
BY END USER, 2023–2030 (USD MILLION) 249
TABLE 324 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN EXOSOME RESEARCH MARKET, JANUARY 2022–MAY 2025 250
TABLE 325 EXOSOME RESEARCH MARKET: DEGREE OF COMPETITION 254
TABLE 326 EXOSOME RESEARCH MARKET: REGION FOOTPRINT 258
TABLE 327 EXOSOME RESEARCH MARKET: OFFERING FOOTPRINT 259
TABLE 328 EXOSOME RESEARCH MARKET: INDICATION FOOTPRINT 260
TABLE 329 EXOSOME RESEARCH MARKET: APPLICATION FOOTPRINT 261
TABLE 330 EXOSOME RESEARCH MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 263
TABLE 331 EXOSOME RESEARCH MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SME PLAYERS, BY OFFERING AND REGION, 2024 264
TABLE 332 EXOSOME RESEARCH MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–MAY 2025 267
TABLE 333 EXOSOME RESEARCH MARKET: DEALS, JANUARY 2022–MAY 2025 268
TABLE 334 EXOSOME RESEARCH MARKET: EXPANSIONS, JANUARY 2022–MAY 2025 269
TABLE 335 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 270
TABLE 336 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 271
TABLE 337 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MAY 2025 273
TABLE 338 QIAGEN: COMPANY OVERVIEW 274
TABLE 339 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 275
TABLE 340 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 276
TABLE 341 LONZA: COMPANY OVERVIEW 277
TABLE 342 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 278
TABLE 343 LONZA: DEALS, JANUARY 2022–MAY 2025 279
TABLE 344 LONZA: EXPANSIONS, JANUARY 2022–MAY 2025 279
TABLE 345 DANAHER: COMPANY OVERVIEW 281
TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 283
TABLE 347 DANAHER: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 283
TABLE 348 DANAHER: DEALS, JANUARY 2022–MAY 2025 284
TABLE 349 BIO-TECHNE: COMPANY OVERVIEW 285
TABLE 350 BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 286
TABLE 351 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 287
TABLE 352 SYSTEM BIOSCIENCES, LLC: COMPANY OVERVIEW 288
TABLE 353 SYSTEM BIOSCIENCES, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 288
TABLE 354 AMSBIO: COMPANY OVERVIEW 290
TABLE 355 AMSBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 291
TABLE 356 ROOSTERBIO, INC.: COMPANY OVERVIEW 292
TABLE 357 ROOSTERBIO, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 292
TABLE 358 ROOSTERBIO, INC.: DEALS, JANUARY 2022–MAY 2025 293
TABLE 359 MILTENYI BIOTEC: COMPANY OVERVIEW 294
TABLE 360 MILTENYI BIOTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 294
TABLE 361 MILTENYI BIOTEC: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 295
TABLE 362 NORGEN BIOTEK CORP.: COMPANY OVERVIEW 296
TABLE 363 NORGEN BIOTEK CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 296
TABLE 364 AETHLON MEDICAL, INC.: COMPANY OVERVIEW 298
TABLE 365 AETHLON MEDICAL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 299
TABLE 366 AETHLON MEDICAL, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 299
TABLE 367 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: COMPANY OVERVIEW 300
TABLE 368 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 300
TABLE 369 SPECTRIS: COMPANY OVERVIEW 301
TABLE 370 SPECTRIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 302
TABLE 371 SPECTRIS: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 303
TABLE 372 SPECTRIS: DEALS, JANUARY 2022–MAY 2025 303
TABLE 373 NANOFCM, INC.: COMPANY OVERVIEW 304
TABLE 374 NANOFCM, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 304
TABLE 375 IZON SCIENCE LIMITED: COMPANY OVERVIEW 305
TABLE 376 IZON SCIENCE LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED 305
TABLE 377 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW 306
TABLE 378 CAPRICOR THERAPEUTICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 307
TABLE 379 ANJARIUM BIOSCIENCES AG: COMPANY OVERVIEW 308
TABLE 380 CILOA: COMPANY OVERVIEW 308
TABLE 381 INNOVAPREP: COMPANY OVERVIEW 309
TABLE 382 ILIAS BIOLOGICS INC.: COMPANY OVERVIEW 309
TABLE 383 UNCHAINED LABS: COMPANY OVERVIEW 310
TABLE 384 RION INC.: COMPANY OVERVIEW 310
TABLE 385 CELL GUIDANCE SYSTEM LLC: COMPANY OVERVIEW 311
TABLE 386 INOVIQ: COMPANY OVERVIEW 312
TABLE 387 NX PHARMAGEN: COMPANY OVERVIEW 312
TABLE 388 EXOPHARM: COMPANY OVERVIEW 313
TABLE 389 EVERZOM: COMPANY OVERVIEW 314
TABLE 390 NANOSOMIX: COMPANY OVERVIEW 314
TABLE 391 CREATIVE BIOLABS: COMPANY OVERVIEW 315
LIST OF FIGURES
FIGURE 1 EXOSOME RESEARCH MARKET SEGMENTATION & REGIONAL SCOPE 32
FIGURE 2 EXOSOME RESEARCH MARKET: YEARS CONSIDERED 33
FIGURE 3 EXOSOME RESEARCH MARKET: RESEARCH DESIGN 36
FIGURE 4 EXOSOME RESEARCH MARKET: KEY DATA FROM SECONDARY SOURCES 38
FIGURE 5 EXOSOME RESEARCH MARKET: BREAKDOWN OF PRIMARIES (SUPPLY-
AND DEMAND-SIDE PARTICIPANTS) 39
FIGURE 6 EXOSOME RESEARCH MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 40
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION:
BOTTOM-UP APPROACH (2024) 41
FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024) 42
FIGURE 9 EXOSOME RESEARCH MARKET: KEY INSIGHTS FROM PRIMARIES 43
FIGURE 10 EXOSOME RESEARCH MARKET: TOP-DOWN APPROACH 44
FIGURE 11 EXOSOME RESEARCH MARKET: CAGR PROJECTIONS 45
FIGURE 12 EXOSOME RESEARCH MARKET: DATA TRIANGULATION 47
FIGURE 13 EXOSOME RESEARCH MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 49
FIGURE 14 EXOSOME RESEARCH MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION) 50
FIGURE 15 EXOSOME RESEARCH MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 50
FIGURE 16 EXOSOME RESEARCH MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 51
FIGURE 17 REGIONAL SNAPSHOT OF EXOSOME RESEARCH MARKET 52
FIGURE 18 HIGH DEMAND FOR PRECISION MEDICINES AND STRONG PHARMACEUTICAL
R&D INFRASTRUCTURE TO DRIVE MARKET 53
FIGURE 19 US AND BIOMARKERS COMMANDED LARGEST SHARE OF NORTH AMERICAN EXOSOME RESEARCH MARKET IN 2024 54
FIGURE 20 US TO WITNESS HIGHEST CAGR FROM 2025 TO 2030 55
FIGURE 21 EXOSOME RESEARCH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 56
FIGURE 22 EXOSOME RESEARCH MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMERS’ BUSINESSES 64
FIGURE 23 INDICATIVE PRICE OF EXOSOME KITS & REAGENTS, BY KEY PLAYER (2024) 66
FIGURE 24 INDICATIVE PRICE OF EXOSOME RESEARCH PRODUCTS, BY REGION (2024) 67
FIGURE 25 EXOSOME RESEARCH MARKET: VALUE CHAIN ANALYSIS 68
FIGURE 26 EXOSOME RESEARCH MARKET: SUPPLY CHAIN ANALYSIS 70
FIGURE 27 EXOSOME RESEARCH MARKET: ECOSYSTEM ANALYSIS 70
FIGURE 28 EXOSOME RESEARCH MARKET: TOP PATENT APPLICANTS/OWNERS
AND NUMBER OF PATENTS GRANTED, JANUARY 2014–DECEMBER 2024 74
FIGURE 29 EXOSOME RESEARCH MARKET: PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 87
FIGURE 31 KEY BUYING CRITERIA FOR TOP THREE END USERS 88
FIGURE 32 EXOSOME RESEARCH MARKET: FUNDING AND NUMBER OF DEALS, 2020–2024 90
FIGURE 33 EXOSOME RESEARCH MARKET: IMPACT OF AI/GEN AI 94
FIGURE 34 NORTH AMERICA: EXOSOME RESEARCH MARKET SNAPSHOT 176
FIGURE 35 EUROPE: EXOSOME RESEARCH MARKET SNAPSHOT 187
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN EXOSOME RESEARCH MARKET,
2020–2024 (USD MILLION) 252
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN EXOSOME RESEARCH
MARKET (2024) 253
FIGURE 38 EXOSOME RESEARCH MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 256
FIGURE 39 EXOSOME RESEARCH MARKET: COMPANY FOOTPRINT 257
FIGURE 40 EXOSOME RESEARCH MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 262
FIGURE 41 EV/EBITDA OF KEY VENDORS 265
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 265
FIGURE 43 EXOSOME RESEARCH MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 266
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 271
FIGURE 45 QIAGEN: COMPANY SNAPSHOT 275
FIGURE 46 LONZA: COMPANY SNAPSHOT 278
FIGURE 47 DANAHER: COMPANY SNAPSHOT 282
FIGURE 48 BIO-TECHNE: COMPANY SNAPSHOT 285
FIGURE 49 AETHLON MEDICAL, INC.: COMPANY SNAPSHOT 298
FIGURE 50 CREATIVE MEDICAL TECHNOLOGIES HOLDINGS, INC.: COMPANY SNAPSHOT 300
FIGURE 51 SPECTRIS: COMPANY SNAPSHOT 302
FIGURE 52 CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT 306
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11